Navigation Links
WuXi PharmaTech Receives GLP Certificate from SFDA for Suzhou Toxicology Facility
Date:8/16/2012

SHANGHAI, Aug. 16, 2012 /PRNewswire-Asia/ -- WuXi PharmaTech (NYSE: WX) today announced that its toxicology facility in Suzhou had received a Certificate of Good Laboratory Practice (GLP) from the State Food and Drug Administration (SFDA) of the People's Republic of China after successfully passing two GLP inspections conducted by the SFDA.  Good Laboratory Practice is a quality system concerned with the organizational processes and conditions under which health safety studies are planned, performed, monitored, recorded, archived, and reported.  The receipt of this GLP certificate is an important acknowledgement by the SFDA about the capability of the Suzhou facility to carry out non-clinical laboratory studies with respect to the requirements of the Chinese Food and Drug Act and SFDA GLP Regulations.

Award of the certificate resulted from a four-day inspection conducted by a team of five inspectors from the SFDA in March 2012.  In addition to an extensive facility assessment, the inspection included an audit of 16 studies in areas that included reproductive toxicology (Segment I and II), carcinogenicity, safety pharmacology, dermal irritation, skin phototoxicity, vascular irritation, and immunology.  The facility inspection evaluated key operational sites, including the vivarium rooms, pharmacy, central archive, and laboratories relating to analytical chemistry, bioanalytical services, toxicokinetics, clinical pathology, histopathology, and immunology.  This successful inspection now expands WuXi's capability to conduct all non-clinical laboratory studies regulated by SFDA.  The facility successfully passed an earlier inspection and received a Certificate of Good Laboratory Practice in 2010. 

In May 2012, WuXi announced that it had received a statement of Good Laboratory Practice from Belgium Scientific Institute of Public Health for the Suzhou toxicology facility.

"WuXi's receipt of this certificate is further acknowledgment that we offer our clients non-clinical laboratory studies that meet national and international GLP quality standards," said Edward Hu, Chief Operating Officer and Chief Financial Officer of WuXi PharmaTech.  "This award is additional confirmation of WuXi capability in offering our pharmaceutical and biotech clients a comprehensive, fully integrated platform of pharmaceutical R&D services."

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States.  As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process.  WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D.  WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec.  For more information, please visit http://www.wuxiapptec.com or contact:

Aaron Shi (for the media)
Tel:   +86-21-5046-4362
Email: Aaron_Shi@wuxiapptec.com

Ronald Aldridge (for investors)
Tel:   +1-201-585-2048
Email: Ron_Aldridge@wuxiapptec.com


'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. WuXi PharmaTech Announces Second-Quarter 2012 Results
2. Pharmatech Oncology Receives Phase 2 SBIR Funding for Just-In-Time Enrollment Model
3. WuXi PharmaTech Announces First-Quarter 2012 Results
4. Industry Leading Pharmaceutical News Website in-Pharmatechnologist.com Refocused and Relaunched
5. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
6. Perrigo Receives FDA Approval And Commences Launch Of Clobetasol Propionate Shampoo, 0.05%
7. GeNO LLC Receives FDA Marketing Clearance For Its Inhaled Nitric Oxide Drug Delivery Device
8. First Warning Systems Receives Investment by Members of the Reno Angels and Local Investors
9. iMD Companies Inc. receives shares of Positive Solutions
10. Genelex Receives First Patent on Business Methods for Pharmacogenetics
11. AcelRx Pharmaceuticals Receives Two Additional U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , March 22, 2017 Under the ... pharmaceutical packaging market size increased year by year ... 2017 to 2021, the market size will maintain ... expected to outnumber RMB140 billion in 2021, thanks ... rapid development of biological agents and supporting policies. ...
(Date:3/22/2017)... -- ImaginAb Inc. today announced the appointment of Martyn Coombs ... chairman of ImaginAb, said "At ImaginAb we have exciting science and ... to our business, particularly in commercializing and making step changes in ... can realize our potential." ... Mr. Coombs is a recognized industry leader in nuclear medicine ...
(Date:3/22/2017)... 22, 2017  CANTEL MEDICAL CORP. (NYSE: CMD ... and CEO, will be presenting at the 16 th ... Central Hotel in New York . The ... 3:00 p.m. ET. In addition, management will be available for ... live audio webcast will be available via the investor relations ...
Breaking Medicine Technology:
(Date:3/22/2017)... ... March 22, 2017 , ... Wash Tower Ltd. has released a series ... Wash Tower, the world's first standalone constant pressure bidet. , The videos in the ... at https://www.washtower.com as well as on its social media pages. , Each ...
(Date:3/22/2017)... ... 2017 , ... The Rett Syndrome Research Trust (RSRT) announced ... afflicts 350,000 individuals worldwide. Rett Syndrome is caused by alterations in a ... Following a normal infancy, Rett Syndrome takes effect in toddlerhood depriving children ...
(Date:3/22/2017)... ... March 22, 2017 , ... Drs. Jennifer Houck, Lauren Smith, Heather ... accept new patients in need of skilled pediatric dentistry in Rock Hill, ... offers pediatric patients routine treatments, including cavities, sealants and fluoride applications, in a comfortable ...
(Date:3/22/2017)... ... March 22, 2017 , ... The Burke Medical ... to translate advances in basic neuroscience at the BMRI labs into new and ... to improve movement, vision, and cognition impaired by stroke, traumatic brain injury, cerebral ...
(Date:3/22/2017)... (PRWEB) , ... March 22, 2017 , ... ... imaging core lab with extensive therapeutic experience and operational excellence in oncology clinical ... immuno-oncology clinical trial for the treatment of non-small cell lung cancer and small ...
Breaking Medicine News(10 mins):